Anahid Ehteda

High Street
Randwick, NSW 2052, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Combined inhibition of FACT and BET disrupts transcription to suppress tumor growth in mouse models of diffuse midline glioma.

Combined inhibition of FACT and BET disrupts transcription to suppress tumor growth in mouse models of diffuse midline glioma.

Journal: Science translational medicine

Published: January 14, 2026

High-throughput in vitro drug screening and in vivo studies identify fenretinide as a brain-penetrant DMG therapeutic.

High-throughput in vitro drug screening and in vivo studies identify fenretinide as a brain-penetrant DMG therapeutic.

Journal: Neuro-oncology

Published: February 12, 2025

Motor-Free Soft Robots for Cancer Detection, Surgery, and In Situ Bioprinting.

Motor-Free Soft Robots for Cancer Detection, Surgery, and In Situ Bioprinting.

Journal: Advanced healthcare materials

Published: November 19, 2024

Microtubule-Targeting Combined with HDAC Inhibition Is a Novel Therapeutic Strategy for Diffuse Intrinsic Pontine Gliomas.

Microtubule-Targeting Combined with HDAC Inhibition Is a Novel Therapeutic Strategy for Diffuse Intrinsic Pontine Gliomas.

Journal: Molecular cancer therapeutics

Published: March 27, 2023

Doxorubicin-Loaded Gold Nanoarchitectures as a Therapeutic Strategy against Diffuse Intrinsic Pontine Glioma.

Doxorubicin-Loaded Gold Nanoarchitectures as a Therapeutic Strategy against Diffuse Intrinsic Pontine Glioma.

Journal: Cancers

Published: February 15, 2021

Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG.

Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG.

Journal: Cell reports

Published: July 23, 2020

Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma.

Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 30, 2020

Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas.

Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas.

Journal: Nature communications

Published: November 20, 2019

Correction to: International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma.

Correction to: International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma.

Journal: Journal of neuro-oncology

Published: November 29, 2018

International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma.

International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma.

Journal: Journal of neuro-oncology

Published: May 22, 2018

Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma.

Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma.

Journal: Oncotarget

Published: August 08, 2017

Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models.

Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models.

Journal: PloS one

Published: September 08, 2016

Showing 1-12 of 22

Last Updated: 09/26/2026